Drug Profile
Research programme: immunoglobulins - Trillium Therapeutics
Latest Information Update: 29 Nov 2021
Price :
$50
*
At a glance
- Originator The Hospital for Sick Children; University Health Network
- Developer The Hospital for Sick Children; Trillium Therapeutics Inc; University Health Network
- Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
- Mechanism of Action SIRPA protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
- 17 Jan 2018 Trillium plans a phase Ia/Ib trial for Lymphoma or Multiple myeloma (Combination therapy, Second line therapy or greater) in Canada in second half of 2018
- 17 Jan 2018 Trillium announces intention to submit IND for TTI 622 to the US-FDA for Cancer in second half of 2017